Biowaiver monographs for immediate release solid oral dosage forms: Mefloquine hydrochloride

Journal of Pharmaceutical Sciences

Volumn 100, Issue 1, 2011, Pages 11-21

  Strauch, S ^a   Jantratid, E ^a,h   Dressman, J B ^a   Junginger, H E ^b   Kopp, S ^c   Midha, K K ^d   Shah, V P ^e   Stavchansky, S ^f   Barends, D M ^g  

^a GOETHE UNIVERSITY   (Germany)

^b NARESUAN UNIVERSITY   (Thailand)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d UNIVERSITY OF SASKATCHEWAN   (Canada)

^e International Pharmaceutical Federation FIP   (Netherlands)

^f UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^g NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^h MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Absorption; Bioavailability; Bioequivalence; Biopharmaceutics Classification System (BCS); Mefloquine hydrochloride; Permeability; Solubility

Indexed keywords

AMMONIUM CALCIUM ALGINATE; CELLULOSE; CROSCARMELLOSE SODIUM; CROSPOVIDONE; DODECYL SULFATE SODIUM; EXCIPIENT; HYDROXYPROPYLCELLULOSE; HYDROXYPROPYLMETHYLCELLULOSE; LACTOSE; MACROGOL; MAGNESIUM STEARATE; MEFLOQUINE; POLOXAMER; POVIDONE; SILICON DIOXIDE; STARCH; TALC; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ABNORMAL DREAMING; ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; AGRANULOCYTOSIS; ANOREXIA; ANXIETY; AREA UNDER THE CURVE; ARTICLE; BALANCE DISORDER; BIOEQUIVALENCE; CLASSIFICATION; CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CUTANEOUS VASCULITIS; DEPRESSION; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG DOSAGE FORM; DRUG ELIMINATION; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG OVERDOSE; DRUG PENETRATION; DRUG SOLUBILITY; DRUG WITHDRAWAL; HALLUCINATION; HUMAN; IMMEDIATE RELEASE FORMULATION; INSOMNIA; NAUSEA; NONHUMAN; PARANOIA; PKA; SIDE EFFECT; SLEEP DISORDER; SOLID; SOMNOLENCE; STEVENS JOHNSON SYNDROME; SUICIDAL IDEATION; VASCULITIS; VOMITING;

EID: 78650067024     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22249     Document Type: Article

References (95)

1. Vogelpoel H, Welink J, Amidon GL, Junginger HE, Midha KK, Möller H, Olling M, Shah VP, Barends DM. 2004. Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: Verapamil hydrochloride, propranolol hydrochloride, and atenolol. J Pharm Sci 93: 1945-1956.
2. World Health Organization (WHO). 2006. Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms. Technical Report Series, No 937, 40th Report, Annex 8 of WHO Expert Committee on Specifications for Pharmaceutical Preparations. Available from: (accessed on October 02, 2009).
3. U.S., Department of Health and Human Services, Food and Drug Administration, Center for Evaluation and Research (CDER). 2000. Guidance for Industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics Classification System. Available from: (accessed on October 02, 2009).
4. European Medicines Agency (EMA). 2008. Committee for Proprietary Medicinal Products (CPMP). Guideline on the Investigation of Bioequivalence-Draft. Available from: (accessed on January 22, 2010).
5. Chuasuwan B, Binjesoh V, Polli JE, Zhang H, Amidon GL, Junginger HE, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. 2009. Biowaiver monographs for immediate release solid oral dosage forms: Diclofenac sodium and diclofenac potassium. J Pharm Sci 98: 1206-1219.
6. Grube S, Langguth P, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. 2009. Biowaiver monographs for immediate release solid oral dosage forms: Quinidine sulfate. J Pharm Sci 98: 2238-2251.
7. Kalantzi L, Reppas C, Dressman JB, Amidon GL, Junginger HE, Midha KK, Shah VP, Stavchansky SA, Barends DM. 2006. Biowaiver monographs for immediate release solid oral dosage forms: Acetaminophen (paracetamol). J Pharm Sci 95: 4-14.
8. Granero GE, Longhi MR, Becker C, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. 2008. Biowaiver monographs for immediate release solid oral dosage forms: Acetazolamide. J Pharm Sci 97: 3691-3699.
9. Arnal J, Gonzalez-Alvarez I, Bermejo M, Amidon GL, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. 2008. Biowaiver monographs for immediate release solid oral dosage forms: Aciclovir. J Pharm Sci 97: 5061-5073.
10. Manzo RH, Olivera ME, Amidon GL, Shah VP, Dressman JB, Barends DM. 2006. Biowaiver monographs for immediate release solid oral dosage forms: Amitriptyline hydrochloride. J Pharm Sci 95: 966-973.
11. Verbeeck RK, Junginger HE, Midha KK, Shah VP, Barends DM. 2005. Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: Chloroquine phosphate, chloroquine sulfate, and chloroquine hydrochloride. J Pharm Sci 94: 1389-1395.
12. Jantratid E, Prakongpan S, Dressman JB, Amidon GL, Junginger HE, Midha KK, Barends DM. 2006. Biowaiver monographs for immediate release solid oral dosage forms: Cimetidine. J Pharm Sci 95: 974-984.
13. Becker C, Dressman JB, Amidon GL, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Barends DM. 2008. Biowaiver monographs for immediate release solid oral dosage forms: Ethambutol dihydrochloride. J Pharm Sci 97: 1350-1360.
14. Potthast H, Dressman JB, Junginger HE, Midha KK, Oeser H, Shah VP, Vogelpoel H, Barends DM. 2005. Biowaiver monographs for immediate release solid oral dosage forms: Ibuprofen. J Pharm Sci 94: 2121-2131.
15. Becker C, Dressman JB, Amidon GL, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Barends DM. 2007. Biowaiver monographs for immediate release solid oral dosage forms: Isoniazid. J Pharm Sci 96: 522-531.
16. Stosik AG, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. 2008. Biowaiver monographs for immediate release solid oral dosage forms: Metoclopramide hydrochloride. J Pharm Sci 97: 3700-3708.
17. Becker C, Dressman JB, Amidon GL, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Barends DM. 2008. Biowaiver monographs for immediate release solid oral dosage forms: Pyrazinamide. J Pharm Sci 97: 3709-3720.
18. Kortejärvi H, Yliperttula M, Dressman JB, Junginger HE, Midha KK, Shah VP, Barends DM. 2005. Biowaiver monographs for immediate release solid oral dosage forms: Ranitidine hydrochloride. J Pharm Sci 94: 1617-1625.
19. Vogt M, Derendorf H, Krämer J, Junginger HE, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. 2007. Biowaiver monographs for immediate release solid oral dosage forms: Prednisolone. J Pharm Sci 96: 27-37.
20. Vogt M, Derendorf H, Krämer J, Junginger HE, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. 2007. Biowaiver monographs for immediate release solid oral dosage forms: Prednisone. J Pharm Sci 96: 1480-1489.
21. Becker C, Dressman JB, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Barends DM. 2009. Biowaiver monographs for immediate release solid oral dosage forms: Rifampicin. J Pharm Sci 98: 2252-2267.
22. Jantratid E, Strauch S, Becker C, Dressman JB, Amidon GL, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Barends DM. 2009. Biowaiver monographs for immediate release solid oral dosage forms: Doxycycline hyclate. J Pharm Sci
23. Granero GE, Longhi MR, Mora MJ, Junginger HE, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. 2009. Biowaiver monographs for immediate release solid oral dosage forms: Furosemide. J Pharm Sci
24. International Federation Pharmaceutical (FIP). Special Interest Group on Biopharmaceutics Classification System (BCS). BCS (Biopharmaceutics Classification System) and Biowaiver. Available from: (accessed on October 02, 2009).
25. Word Health Organization (WHO). 1975. International Nonproprietary Names for pharmaceutical substances-Mefloquine. WHO Chronicle, Vol. 29, No. 3. Available from: (accessed on October 02, 2009).
26. The European Pharmacopoeia (Ph.Eur.). 2002. Pharm. Eur. Kommentar (German), NT 2001-Mefloquinhydrochlorid/Mefloquini hydrochloridum. 15th edition. Eschborn/Stuttgart: GOVI-Verlag-Pharmazeutischer Verlag GmbH, Wissenschaftliche Verlagsgesellschaft mbH.
27. PubChem. 2008. PubChem Substance: Mefloquine-Substance Summary. Available from: (accessed on October 02, 2009).
28. The Merck Index. 2006. 14th ed., Whitehouse Station, NJ, USA.
29. Roche Pharma AG. 2007. Fachinformation Lariam (German). Rote Liste Service GmbH. Available from: (accessed on October 02, 2009).
30. World Health Organization (WHO). 2001. The use of antimalarial drugs-Part II: 1.5 Mefloquine. Roll Back Malaria/World Health Organisation. Available from: (accessed on October 02, 2009).
31. Mepha Pharma AG. 2006. Mephaquin-Product Information for the Medicinal Professionals. Available from: (accessed on December 22, 2009).
32. Crevoisier C, Handschin J, Barre J, Roumenov D, Kleinbloesem C. 1997. Food increases the bioavailability of mefloquine. Eur J Clin Pharmacol 53: 135-139.
33. White NJ. 1985. Clinical pharmacokinetics of antimalarial drugs. Clin Pharmacokinet 10: 187-215.
34. Lobel HO, Miani M, Eng T, Bernard KW, Hightower AW, Campbell CC. 1993. Long-term malaria prophylaxis with weekly mefloquine. Lancet 341: 848-851.
35. Sweetman S. 2006. Martindale: The complete drug reference. London: Pharmaceutical Press.
36. Arthur JD, Shanks GD, Echeverria P. 1990. Mefloquine prophylaxis. Lancet 335: 972.
37. Huzly D, Schonfeld C, Beuerle W, Bienzle U. 1996. Malaria chemoprophylaxis in German tourists: A prospective study on compliance and adverse reactions. J Travel Med 3: 148-155.
38. Schlagenhauf P, Steffen R. 2000. Neuropsychiatric events and travel: Do antimalarials play a role? J Travel Med 7: 225-226.
39. Hoebe C, de Munter J, Thijs C. 1997. Adverse effects and compliance with mefloquine or proguanil antimalarial chemoprophylaxis. Eur J Clin Pharmacol 52: 269-275.
40. Hennequin C, Bouree P, Halfon P. 1991. Agranulocytosis during treatment with mefloquine. Lancet 337: 984.
41. Van den Enden E, Van Gompel A, Colebunders R, Van den Ende J. 1991. Mefloquine-induced Stevens-Johnson syndrome. Lancet 337: 683.
42. White AC, Jr., Gard DA, Sessoms SL. 1995. Cutaneous vasculitis associated with mefloquine. Ann Int Med 123: 894.
43. Scerri L, Pace JL. 1993. Mefloquine-associated cutaneous vasculitis. Int J Dermatol 32: 517-518.
44. Beylot C, Doutre MS, Beylot-Barry M. 1996. Acute generalized exanthematous pustulosis. Semin Cutan Med Surg 15: 244-249.
45. Patchen LC, Campbell CC, Williams SB. 1989. Neurologic reactions after a therapeutic dose of mefloquine. N Engl J Med 321: 1415-1416.
46. Weinke T, Trautmann M, Held T, Weber G, Eichenlaub D, Fleischer K, Kern W, Pohle HD. 1991. Neuropsychiatric side effects after the use of mefloquine. Am J Trop Med Hyg 45: 86-91.
47. Lobel HO, Baker MA, Gras FA, Stennies GM, Meerburg P, Hiemstra E, Parise M, Odero M, Waiyaki P. 2001. Use of malaria prevention measures by North American and European travelers to East Africa. J Travel Med 8: 167-172.
48. Barrett PJ, Emmins PD, Clarke PD, Bradley DJ. 1996. Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: Postal and telephone survey of travellers. BMJ 313: 525-528.
49. van Riemsdijk MM, Sturkenboom MC, Pepplinkhuizen L, Stricker BH. 2005. Mefloquine increases the risk of serious psychiatric events during travel abroad: A nationwide case-control study in the Netherlands. J Clin Psychiatry 66: 199-204.
50. Wittes RC, Saginur R. 1995. Adverse reaction to mefloquine associated with ethanol ingestion. CMAJ 152: 515-517.
51. van Riemsdijk MM, Sturkenboom MC, Ditters JM, Tulen JH, Ligthelm RJ, Overbosch D, Stricker BH. 2004. Low body mass index is associated with an increased risk of neuropsychiatric adverse events and concentration impairment in women on mefloquine. Br J Clin Pharmacol 57: 506-512.
52. Hoffmann-La Roche Inc. 2009. Lariam Medication Guide. Available from: (accessed on November 19, 2009).
53. Slutsker LM, Khoromana CO, Payne D, Allen CR, Wirima JJ, Heymann DL, Patchen L, Steketee RW. 1990. Mefloquine therapy for Plasmodium falciparum malaria in children under 5 years of age in Malawi: In vivo/in vitro efficacy and correlation of drug concentration with parasitological outcome. Bull World Health Organ 68: 53-59.
54. Nosten F, ter Kuile F, Chongsuphajaisiddhi T, Na Bangchang K, Karbwang J, White NJ. 1991. Mefloquine pharmacokinetics and resistance in children with acute falciparum malaria. Br J Clin Pharmacol 31: 556-559.
55. The European Pharmacopoeia 6.0, (Ph.Eur., 6., 0). 2007. 6th ed., Strasbourg, France: European Directorate for the Quality of Medicines, Council of Europe.
56. Lim P. 1985. Mefloquine hydrochloride. In: Florey K, editor. Analytical profiles of Drug Substances. Orlando: Academic Press. Vol. 14, pp 157-180.
57. Kiss A, Repasi J, Salamon Z, Novak C, Pokol G, Tomor K. 1994. Solid state investigation of mefloquine hydrochloride. J Pharm Biomed Anal 12: 889-893.
58. Weidekamm E, Rusing G, Caplain H, Sorgel F, Crevoisier C. 1998. Lack of bioequivalence of a generic mefloquine tablet with the standard product. Eur J Clin Pharmacol 54: 615-619.
59. Jack DB. 1992. Handbook of clinical pharmacokinetic data. 1st edition. Hampshire, UK: Macmillan Publishers Ltd.
60. Wishart D. 2007. Mefloquine (DB00358). Dept. of Computing Science and Biological Science. Available from: (accessed on October 02, 2009).
61. World Health Organization (WHO). 2009. WHO Model List of Essential Medicines. Available from: (accessed on October 02, 2009).
62. Arzneimittel-Kompendium der Schweiz. 2008. Documed AG, Switzerland. Available from: (accessed on October 02, 2009).
63. Rote Liste. 2008. Rote Liste Service GmbH. Available from: (accessed on October 02, 2009).
64. Lægemiddel Styrelsen, Danish Medicines Agency. 2009. Available from: (accessed on June 25, 2009).
65. Fimea, Finnish Medicines Agency. 2009. Available from: (accessed on June 25, 2009).
66. VIDAL, L'information de référence sur les produits de santé. 2009. Available from: (accessed on June 25, 2009).
67. College ter Beoordeling van Geneesmiddelen, Medicines Evaluation Board. 2009. Available from: (accessed on June 25, 2009).
68. Statens legemiddelverket. 2009. Available from: (accessed on June 25, 2009).
69. Agencia Española de Medicamentos y Productos Sanitarios. 2009. Available from: (accessed on June 25, 2009).
70. Läkemedelsverket. 2009. Available from: (accessed on June 25, 2009).
71. Medicines.org.uk. 2009. Available from: (accessed on June 25, 2009).
72. DailyMed, Current Medication Information. 2009. Available from: (accessed on June 25, 2009).
73. U.S., Department of Health and Human Services, Food and Drug Administration, Center for Evaluation and Research (CDER). 2009. Drugs @ FDA, FDA Approved Drug Products: Mefloquine hydrochloride. Available from: (accessed on December 22, 2009).
74. Mefloquine (Lariam) Action, Information and Support Service. 1997. Mefloquine (Lariam) Action. Available from: (accessed on December 22, 2009).
75. Desjardins RE, Pamplin CL III, von Bredow J, Barry KG, Canfield CJ. 1979. Kinetics of a new antimalarial, mefloquine. Clin Pharmacol Ther 26: 372-379.
76. Looareesuwan S, White NJ, Warrell DA, Forgo I, Dubach UG, Ranalder UB, Schwartz DE. 1987. Studies of mefloquine bioavailability and kinetics using a stable isotope technique: A comparison of Thai patients with falciparum malaria and healthy Caucasian volunteers. Br J Clin Pharmacol 24: 37-42.
77. Karbwang J, White NJ. 1990. Clinical pharmacokinetics of mefloquine. Clin Pharmacokinet 19: 264-279.
78. Pham YT, Regina A, Farinotti R, Couraud P, Wainer IW, Roux F, Gimenez F. 2000. Interactions of racemic mefloquine and its enantiomers with P-glycoprotein in an immortalised rat brain capillary endothelial cell line, GPNT. Biochim Biophys Acta 1524: 212-219.
79. Wu CY, Benet LZ. 2005. Predicting drug disposition via application of BCS: Transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 22: 11-23.
80. Fitch CD, Chan RL, Chevli R. 1979. Chloroquine resistance in malaria: Accessibility of drug receptors to mefloquine. Antimicrob Agents Chemother 15: 258-262.
81. Franssen G, Rouveix B, Lebras J, Bauchet J, Verdier F, Michon C, Bricaire F. 1989. Divided-dose kinetics of mefloquine in man. Br J Clin Pharmacol 28: 179-184.
82. Schwartz DE, Eckert G, Hartmann D, Weber B, Richard-Lenoble D, Ekue JM, Gentilini M. 1982. Single dose kinetics of mefloquine in man. Plasma levels of the unchanged drug and of one of its metabolites. Chemotherapy 28: 70-84.
83. Na-Bangchang K, Karbwang J, Palacios PA, Ubalee R, Saengtertsilapachai S, Wernsdorfer WH. 2000. Pharmacokinetics and bioequivalence evaluation of three commercial tablet formulations of mefloquine when given in combination with dihydroartemisinin in patients with acute uncomplicated falciparum malaria. Eur J Clin Pharmacol 55: 743-748.
84. Mepha Pharma AG. 2006. Summary of product characteristics-Mephaquin Lactab. Available from (accessed date: June 25, 2008).
85. World Health Organization (WHO). 2008. The International Pharmacopoeia, 4th edition (incl. first supplement). Available from: (accessed on December 21, 2009).
86. The Japanese Pharmacopoeia 15 (JP XV). 2006. 15th ed. Ministry of Health, Labour and Welfare.
87. The United States Pharmacopeia (USP29). 2006. 29th ed., Rockville, MD: United States Pharmacopeial Convention Inc.
88. U.S., Department of Health and Human Services, Food and Drug Administration, Center for Evaluation and Research (CDER). 1995. Guidance for Industry. Immediate release solid oral dosage forms scale-up and postapproval changes: Chemistry, manufacturing, and controls, in vitro dissolution testing, and in vivo bioequivalence documentation. Available from: (accessed on October 02, 2009).
89. Kasim NA, Whitehouse M, Ramachandran C, Bermejo M, Lennernas H, Hussain AS, Junginger HE, Stavchansky SA, Midha KK, Shah VP, Amidon GL. 2004. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm 1: 85-96.
90. Lindenberg M, Kopp S, Dressman JB. 2004. Classification of orally administered drugs on the World Health Organization Model List of Essential Medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm 58: 265-278.
91. Karbwang J, Na Bangchang K, Thanavibul A, Back DJ, Bunnag D, Harinasuta T. 1994. Pharmacokinetics of mefloquine alone or in combination with artesunate. Bull World Health Organ 72: 83-87.
92. Karbwang J, Na-Bangchang K. 1994. Clinical application of mefloquine pharmacokinetics in the treatment of P. falciparum malaria. Fundam Clin Pharmacol 8: 491-502.
93. Pan American Health Organization (PAHO). Regional Office of The World Health Organization, Pan American Network for Drug Regulatory Harmonization. 2005. Science Based Criteria for bioequivalence testing (in vitro and in vivo), Biowaivers and Strategy for Implementation. Available from: (accessed on October 02, 2009).
94. Croft A, Garner P. 1997. Mefloquine to prevent malaria: A systematic review of trials. BMJ 315: 1412-1416.
95. European Commission. 2006. Guideline on dossier requirements for Type IA and IB notifications. Available from: c/var_type_1a1b_guideline_06-2006.pdf (accessed on October02, 2009).